The CAMKK2-AMPK Kinase Pathway Mediates the Synaptotoxic Effects of Aβ Oligomers through Tau Phosphorylation

Neuron

Volumn 78, Issue 1, 2013, Pages 94-108

  Mairet Coello, Georges ^a   Courchet, Julien ^a   Pieraut, Simon ^a   Courchet, Virginie ^a   Maximov, Anton ^a   Polleux, Franck ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM ION; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA 2; METFORMIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CALCIUM CELL LEVEL; CELL DENSITY; CELL LOSS; CELLULAR DISTRIBUTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC SPINE; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITION; EXCITOTOXICITY; FEMALE; HIPPOCAMPAL CA3 REGION; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; MEMBRANE DEPOLARIZATION; MOLECULAR DYNAMICS; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PYRAMIDAL NERVE CELL; SYNAPTOTOXICITY; TRANSGENIC MOUSE;

ACTION POTENTIALS; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CALCIUM; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE KINASE; CELLS, CULTURED; DENDRITIC SPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPORATION; EMBRYO, MAMMALIAN; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUTAMIC ACID; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; NEURONS; PATCH-CLAMP TECHNIQUES; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASES; SERINE; TAU PROTEINS; TRANSFECTION;

EID: 84876078566     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2013.02.003     Document Type: Article

References (82)

1. Ageta-Ishihara N., Takemoto-Kimura S., Nonaka M., Adachi-Morishima A., Suzuki K., Kamijo S., Fujii H., Mano T., Blaeser F., Chatila T.A., et al. Control of cortical axon elongation by a GABA-driven Ca2+/calmodulin-dependent protein kinase cascade. J. Neurosci. 2009, 29:13720-13729.
2. Alessi D.R., Sakamoto K., Bayascas J.R. LKB1-dependent signaling pathways. Annu. Rev. Biochem. 2006, 75:137-163.
3. Anderson K.A., Ribar T.J., Lin F., Noeldner P.K., Green M.F., Muehlbauer M.J., Witters L.A., Kemp B.E., Means A.R. Hypothalamic CaMKK2 contributes to the regulation of energy balance. Cell Metab. 2008, 7:377-388.
4. Barnes A.P., Lilley B.N., Pan Y.A., Plummer L.J., Powell A.W., Raines A.N., Sanes J.R., Polleux F. LKB1 and SAD kinases define a pathway required for the polarization of cortical neurons. Cell 2007, 129:549-563.
5. Bezprozvanny I., Mattson M.P. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 2008, 31:454-463.
6. Biernat J., Gustke N., Drewes G., Mandelkow E.M., Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 1993, 11:153-163.
7. Bright N.J., Carling D., Thornton C. Investigating the regulation of brain-specific kinases 1 and 2 by phosphorylation. J. Biol. Chem. 2008, 283:14946-14954.
8. Chatterjee S., Sang T.K., Lawless G.M., Jackson G.R. Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a Drosophila model. Hum. Mol. Genet. 2009, 18:164-177.
9. Chen Y., Zhou K., Wang R., Liu Y., Kwak Y.D., Ma T., Thompson R.C., Zhao Y., Smith L., Gasparini L., et al. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc. Natl. Acad. Sci. USA 2009, 106:3907-3912.
10. Chromy B.A., Nowak R.J., Lambert M.P., Viola K.L., Chang L., Velasco P.T., Jones B.W., Fernandez S.J., Lacor P.N., Horowitz P., et al. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 2003, 42:12749-12760.
11. Coleman P.D., Yao P.J. Synaptic slaughter in Alzheimer's disease. Neurobiol. Aging 2003, 24:1023-1027.
12. Culmsee C., Monnig J., Kemp B.E., Mattson M.P. AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J. Mol. Neurosci. 2001, 17:45-58.
13. Davies C.A., Mann D.M., Sumpter P.Q., Yates P.O. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J. Neurol. Sci. 1987, 78:151-164.
14. De Felice F.G., Velasco P.T., Lambert M.P., Viola K., Fernandez S.J., Ferreira S.T., Klein W.L. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 2007, 282:11590-11601.
15. De Felice F.G., Wu D., Lambert M.P., Fernandez S.J., Velasco P.T., Lacor P.N., Bigio E.H., Jerecic J., Acton P.J., Shughrue P.J., et al. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol. Aging 2008, 29:1334-1347.
16. Demuro A., Mina E., Kayed R., Milton S.C., Parker I., Glabe C.G. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 2005, 280:17294-17300.
17. Eroglu C., Barres B.A. Regulation of synaptic connectivity by glia. Nature 2010, 468:223-231.
18. Fogarty S., Hawley S.A., Green K.A., Saner N., Mustard K.J., Hardie D.G. Calmodulin-dependent protein kinase kinase-beta activates AMPK without forming a stable complex: synergistic effects of Ca2+ and AMP. Biochem. J. 2010, 426:109-118.
19. Gadalla A.E., Pearson T., Currie A.J., Dale N., Hawley S.A., Sheehan M., Hirst W., Michel A.D., Randall A., Hardie D.G., Frenguelli B.G. AICA riboside both activates AMP-activated protein kinase and competes with adenosine for the nucleoside transporter in the CA1 region of the rat hippocampus. J. Neurochem. 2004, 88:1272-1282.
20. Green M.F., Anderson K.A., Means A.R. Characterization of the CaMKKβ-AMPK signaling complex. Cell. Signal. 2011, 23:2005-2012.
21. Hardie D.G. Neither LKB1 nor AMPK are the direct targets of metformin. Gastroenterology 2006, 131:973.
22. Hardie D.G. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 2007, 8:774-785.
23. Hassing L.B., Johansson B., Nilsson S.E., Berg S., Pedersen N.L., Gatz M., McClearn G. Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer's disease: a population-based study of the oldest old. Int. Psychogeriatr. 2002, 14:239-248.
24. Hawley S.A., Boudeau J., Reid J.L., Mustard K.J., Udd L., Mäkelä T.P., Alessi D.R., Hardie D.G. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2003, 2:28.
25. Hawley S.A., Pan D.A., Mustard K.J., Ross L., Bain J., Edelman A.M., Frenguelli B.G., Hardie D.G. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2005, 2:9-19.
26. Hawley S.A., Ross F.A., Chevtzoff C., Green K.A., Evans A., Fogarty S., Towler M.C., Brown L.J., Ogunbayo O.A., Evans A.M., Hardie D.G. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 2010, 11:554-565.
27. Hoover B.R., Reed M.N., Su J., Penrod R.D., Kotilinek L.A., Grant M.K., Pitstick R., Carlson G.A., Lanier L.M., Yuan L.L., et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 2010, 68:1067-1081.
28. Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., Kholodenko D., Malenka R.C., Nicoll R.A., Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA 1999, 96:3228-3233.
29. Hsieh H., Boehm J., Sato C., Iwatsubo T., Tomita T., Sisodia S., Malinow R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 2006, 52:831-843.
30. Hundal R.S., Krssak M., Dufour S., Laurent D., Lebon V., Chandramouli V., Inzucchi S.E., Schumann W.C., Petersen K.F., Landau B.R., Shulman G.I. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000, 49:2063-2069.
31. Hurley R.L., Anderson K.A., Franzone J.M., Kemp B.E., Means A.R., Witters L.A. The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J. Biol. Chem. 2005, 280:29060-29066.
32. Iijima K., Gatt A., Iijima-Ando K. Tau Ser262 phosphorylation is critical for Abeta42-induced tau toxicity in a transgenic Drosophila model of Alzheimer's disease. Hum. Mol. Genet. 2010, 19:2947-2957.
33. Ittner L.M., Ke Y.D., Delerue F., Bi M., Gladbach A., van Eersel J., Wölfing H., Chieng B.C., Christie M.J., Napier I.A., et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010, 142:387-397.
34. Jacobsen J.S., Wu C.C., Redwine J.M., Comery T.A., Arias R., Bowlby M., Martone R., Morrison J.H., Pangalos M.N., Reinhart P.H., Bloom F.E. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2006, 103:5161-5166.
35. Jaleel M., McBride A., Lizcano J.M., Deak M., Toth R., Morrice N.A., Alessi D.R. Identification of the sucrose non-fermenting related kinase SNRK, as a novel LKB1 substrate. FEBS Lett. 2005, 579:1417-1423.
36. Jin M., Shepardson N., Yang T., Chen G., Walsh D., Selkoe D.J. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl. Acad. Sci. USA 2011, 108:5819-5824.
37. Ju T.C., Chen H.M., Lin J.T., Chang C.P., Chang W.C., Kang J.J., Sun C.P., Tao M.H., Tu P.H., Chang C., et al. Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease. J. Cell Biol. 2011, 194:209-227.
38. Klein W.L. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 2002, 41:345-352.
39. Kuramoto N., Wilkins M.E., Fairfax B.P., Revilla-Sanchez R., Terunuma M., Tamaki K., Iemata M., Warren N., Couve A., Calver A., et al. Phospho-dependent functional modulation of GABA(B) receptors by the metabolic sensor AMP-dependent protein kinase. Neuron 2007, 53:233-247.
40. Lacor P.N., Buniel M.C., Chang L., Fernandez S.J., Gong Y., Viola K.L., Lambert M.P., Velasco P.T., Bigio E.H., Finch C.E., et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci. 2004, 24:10191-10200.
41. Lacor P.N., Buniel M.C., Furlow P.W., Clemente A.S., Velasco P.T., Wood M., Viola K.L., Klein W.L. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 2007, 27:796-807.
42. Lim M.A., Selak M.A., Xiang Z., Krainc D., Neve R.L., Kraemer B.C., Watts J.L., Kalb R.G. Reduced activity of AMP-activated protein kinase protects against genetic models of motor neuron disease. J. Neurosci. 2012, 32:1123-1141.
43. Lizcano J.M., Göransson O., Toth R., Deak M., Morrice N.A., Boudeau J., Hawley S.A., Udd L., Mäkelä T.P., Hardie D.G., Alessi D.R. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 2004, 23:833-843.
44. Lopez-Lopez C., Dietrich M.O., Metzger F., Loetscher H., Torres-Aleman I. Disturbed cross talk between insulin-like growth factor I and AMP-activated protein kinase as a possible cause of vascular dysfunction in the amyloid precursor protein/presenilin 2 mouse model of Alzheimer's disease. J. Neurosci. 2007, 27:824-831.
45. MacKnight C., Rockwood K., Awalt E., McDowell I. Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement. Geriatr. Cogn. Disord. 2002, 14:77-83.
46. Mandelkow E.M., Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb. Perspect. Med. 2012, 2:a006247.
47. Masliah E., Mallory M., Alford M., DeTeresa R., Hansen L.A., McKeel D.W., Morris J.C. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 2001, 56:127-129.
48. Mattson M.P., Cheng B., Davis D., Bryant K., Lieberburg I., Rydel R.E. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 1992, 12:376-389.
49. McCullough L.D., Zeng Z., Li H., Landree L.E., McFadden J., Ronnett G.V. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke. J. Biol. Chem. 2005, 280:20493-20502.
50. Mihaylova M.M., Shaw R.J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 2011, 13:1016-1023.
51. Momcilovic M., Hong S.P., Carlson M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J. Biol. Chem. 2006, 281:25336-25343.
52. Moolman D.L., Vitolo O.V., Vonsattel J.P., Shelanski M.L. Dendrite and dendritic spine alterations in Alzheimer models. J. Neurocytol. 2004, 33:377-387.
53. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000, 20:4050-4058.
54. Nishimura I., Yang Y., Lu B. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 2004, 116:671-682.
55. Palop J.J., Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 2010, 13:812-818.
56. Palop J.J., Chin J., Roberson E.D., Wang J., Thwin M.T., Bien-Ly N., Yoo J., Ho K.O., Yu G.Q., Kreitzer A., et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007, 55:697-711.
57. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F.R., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
58. Roberson E.D., Halabisky B., Yoo J.W., Yao J., Chin J., Yan F., Wu T., Hamto P., Devidze N., Yu G.Q., et al. Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 2011, 31:700-711.
59. Salminen A., Kaarniranta K., Haapasalo A., Soininen H., Hiltunen M. AMP-activated protein kinase: a potential player in Alzheimer's disease. J. Neurochem. 2011, 118:460-474.
60. Schon E.A., Przedborski S. Mitochondria: the next (neurode)generation. Neuron 2011, 70:1033-1053.
61. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 2007, 27:2866-2875.
62. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
63. Shaw R.J., Kosmatka M., Bardeesy N., Hurley R.L., Witters L.A., DePinho R.A., Cantley L.C. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. USA 2004, 101:3329-3335.
64. Son S.M., Jung E.S., Shin H.J., Byun J., Mook-Jung I. Aβ-induced formation of autophagosomes is mediated by RAGE-CaMKKβ-AMPK signaling. Neurobiol. Aging 2012, 33. 1006.e11-23.
65. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30:572-580.
66. Thornton C., Bright N.J., Sastre M., Muckett P.J., Carling D. AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid β-peptide exposure. Biochem. J. 2011, 434:503-512.
67. Tokumitsu H., Inuzuka H., Ishikawa Y., Ikeda M., Saji I., Kobayashi R. STO-609, a specific inhibitor of the Ca(2+)/calmodulin-dependent protein kinase kinase. J. Biol. Chem. 2002, 277:15813-15818.
68. Vingtdeux V., Giliberto L., Zhao H., Chandakkar P., Wu Q., Simon J.E., Janle E.M., Lobo J., Ferruzzi M.G., Davies P., Marambaud P. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J. Biol. Chem. 2010, 285:9100-9113.
69. Vingtdeux V., Chandakkar P., Zhao H., d'Abramo C., Davies P., Marambaud P. Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-β peptide degradation. FASEB J. 2011, 25:219-231.
70. Vingtdeux V., Davies P., Dickson D.W., Marambaud P. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathol. 2011, 121:337-349.
71. Viollet B., Andreelli F., Jørgensen S.B., Perrin C., Flamez D., Mu J., Wojtaszewski J.F., Schuit F.C., Birnbaum M., Richter E., et al. Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. Biochem. Soc. Trans. 2003, 31:216-219.
72. Waxman E.A., Giasson B.I. Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J. Neurosci. 2011, 31:7604-7618.
73. Wei W., Nguyen L.N., Kessels H.W., Hagiwara H., Sisodia S., Malinow R. Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat. Neurosci. 2010, 13:190-196.
74. Williams T., Brenman J.E. LKB1 and AMPK in cell polarity and division. Trends Cell Biol. 2008, 18:193-198.
75. Woods A., Johnstone S.R., Dickerson K., Leiper F.C., Fryer L.G., Neumann D., Schlattner U., Wallimann T., Carlson M., Carling D. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 2003, 13:2004-2008.
76. Woods A., Dickerson K., Heath R., Hong S.P., Momcilovic M., Johnstone S.R., Carlson M., Carling D. Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab. 2005, 2:21-33.
77. Yi J.J., Barnes A.P., Hand R., Polleux F., Ehlers M.D. TGF-beta signaling specifies axons during brain development. Cell 2010, 142:144-157.
78. Yoon S.O., Park D.J., Ryu J.C., Ozer H.G., Tep C., Shin Y.J., Lim T.H., Pastorino L., Kunwar A.J., Walton J.C., et al. JNK3 perpetuates metabolic stress induced by Aβ peptides. Neuron 2012, 75:824-837.
79. Yoshida H., Goedert M. Phosphorylation of microtubule-associated protein tau by AMPK-related kinases. J. Neurochem. 2012, 120:165-176.
80. Yu W., Polepalli J., Wagh D., Rajadas J., Malenka R., Lu B. A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines. Hum. Mol. Genet. 2012, 21:1384-1390.
81. Zempel H., Thies E., Mandelkow E., Mandelkow E.M. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J. Neurosci. 2010, 30:11938-11950.
82. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001, 108:1167-1174.